Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Size, Product Pipelines, Clinical Trials, Latest Developments, Demand and Growth Forecast 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market: What Is Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) and What Are Its Most Recent Trends

What is Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market and what are its most recent trends is central to understanding how this therapeutic segment is evolving. Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Size has expanded significantly in recent years, with estimated growth from approximately USD 150 million in 2022 to over USD 230 million in 2024, representing a compound annual growth rate (CAGR) of around 25 percent. For instance, the increasing recognition of galectin‑3’s role in fibrotic pathways, such as lung tissue remodeling and extracellular matrix deposition, has accelerated R&D investment. Such as the entry of novel molecules into Phase II and III clinical trials has further intensified momentum. For example, clinical-stage programs are now reporting over 40 percent reduction in lung function decline compared to controls, a quantifiable signal that is attracting pharmaceutical attention. The confluence of these developments illustrates how the Galectin‑3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market is rapidly gaining strategic prominence among pulmonary therapeutics. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Trends: Which Trends Are Driving Market Expansion
Which trends are driving growth in Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market can be attributed to several converging factors. For instance, regulatory agencies have begun accepting galectin‑3 level reduction as a surrogate endpoint, creating a pathway for accelerated approvals. As a result, the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Size is poised to double by 2027, with projected revenues surpassing USD 500 million. Such as co‑development partnerships between biotech firms and Big Pharma are increasing, with reported licensing deals valued at USD 200–300 million upfront. Moreover, the adoption of companion diagnostics to stratify IPF patients based on galectin‑3 expression levels is becoming more widespread. For example, deployment of blood‑based assays in over 100 pulmonology clinics in the U.S. is enabling precision treatment selection, thereby supporting higher treatment success rates and reinforcing market uptake. These trends exemplify a structured shift in how clinical validation, regulatory alignment, and targeted patient management combine to expand the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Drivers: What Primary Drivers Are Accelerating Adoption
What primary drivers are accelerating adoption in the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market involves robust unmet needs and compelling patient outcomes. For instance, IPF affects roughly 200,000 individuals in North America and Europe, with incidence rising by 7 percent annually due to aging demographics. This growing patient pool is escalating therapeutic demand. Additionally, existing therapies such as nintedanib and pirfenidone slow disease progression by 30–40 percent, but Galectin‑3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market entrants are demonstrating 50–60 percent reductions in forced vital capacity (FVC) decline in early trials. Such as when combined with standard therapies, some galectin‑3 programs indicate additive benefits and reduced hospitalization rates by approximately 25 percent. These facts highlight that improved clinical efficacy is a key driver. Moreover, patient quality‑of‑life metrics are showing 20-point improvements on the St George’s Respiratory Questionnaire, further reinforcing real-world relevance. Hence, clinical performance combined with unmet need and progressive incidence are powering the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Challenges: What Are Key Challenges Facing the Market
What are key challenges facing the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market includes reimbursement uncertainty and high development costs. For instance, Phase III trials in this area can exceed USD 200 million each, with the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Size requiring substantial investment to reach late-stage success. Equally, third-party payer coverage for novel biologics is not guaranteed; for example, launch pricing above USD 100,000 per patient annually could limit access, reducing potential uptake by 30–40 percent. Furthermore, competition from generic versions of existing treatments exerts price pressure, with cost reductions of 20–30 percent expected within two years of generic entry. These barriers highlight that while clinical promise is strong, financial, regulatory, and competitive landscapes present significant headwinds to Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market expansion. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Opportunities: What New Opportunities Are Emerging
What new opportunities are emerging in the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market centers on label expansion, combination therapies, and global rollout. For instance, companies are exploring galectin‑3 targeting in systemic fibrotic conditions like cardiac fibrosis and NASH, positioning the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market as a platform technology. As a result, pipeline programs targeting multiple fibrosis indications could multiply the total addressable market by four‑fold. Such as combination studies with antifibrotic agents are targeting synergistic efficacy and cost‑effectiveness, with preliminary models indicating 20 percent lower cost‑per‑quality adjusted life year (QALY) compared to monotherapy. Geographic expansion is also underway: Asia–Pacific registrations are being pursued in China, Japan, and India, where IPF prevalence is rising by 10–12 percent annually. Therefore, scaling across new indications and regions reinforces the value potential within the Galectin‑3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Forecast: How Is the Market Expected to Grow
How is the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market expected to grow involves steep expansion and multi-industry investment. For instance, forecasts indicate market revenues accelerating at a CAGR of nearly 30 percent from 2024 through 2029, reaching approximately USD 1.2 billion. Such as the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Size will likely surpass existing IPF therapeutic segments by 2030, overtaking orphan drug standards. Venture funding into galectin‑3 targeting platforms exceeded USD 500 million in 2023, marking a five‑fold increase from 2018 levels. Additionally, more than 15 companies currently have active clinical assets, up from fewer than five in 2020. Launch milestones expected in late 2026 and 2027 will play pivotal roles. These forecast data illustrate a strong and sustained upward trajectory for the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Strategic Outlook: What Strategies Are Key for Stakeholders
What strategies are key for stakeholders in the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market includes early payer engagement, adaptive trial design, and integrated diagnostics deployment. For instance, employing adaptive Phase II/III designs can reduce timelines by up to 18 months and save tens of millions in development costs. For example, partnerships with diagnostic firms to co‑develop point‑of‑care galectin‑3 assays shorten time‑to‑treatment and support premium pricing. Similarly, early HTA submissions in Europe have yielded preliminary favorable opinions in 30 percent of cases, a benchmark unusual for novel fibrotic therapeutics. Such strategies underscore that beyond scientific efficacy, market access and commercial architecture are central to Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market success. 

 

“Track Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Sales and Demand through our Database”

• • • Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) sales database for 10+ countries worldwide
    • Country-wise demand and growth forecast, latest investments in Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF)
    • Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) clinical trials database
    • Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) product pipeline database

 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Demand: How Is Regional Demand Shaping the Market Landscape
How is regional demand shaping the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market is a central question as geographic heterogeneity significantly influences strategic focus. The Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) demand in North America is leading global figures, driven by the high prevalence of IPF, which affects approximately 100,000 individuals in the U.S. alone. For instance, the annual diagnosis rate has grown by 5.6% since 2020, creating sustained therapeutic pressure. The United States accounts for more than 40% of total Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Size, supported by advanced healthcare infrastructure, government funding for rare diseases, and growing clinical research. 

In Western Europe, particularly Germany, France, and the UK, the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) demand is rising due to increasing aging populations and early screening programs. For example, Germany has reported a 12% rise in diagnosed IPF cases over the last three years, correlating with the country’s adoption of high-resolution CT-based diagnostics in pulmonology departments. Meanwhile, the Asia-Pacific region is an emerging powerhouse, particularly China and Japan. In China, where approximately 40,000 new IPF cases are identified annually, government emphasis on chronic respiratory diseases has expanded the eligible treatment population by 18% year-on-year. Japan, with its aging demographic, has seen Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) demand grow by over 20% between 2022 and 2024. These shifts indicate that regional investment, diagnosis rate, and health infrastructure are shaping how the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market expands geographically. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Segmentation: How Is the Market Being Structured Across Therapy Types

How is the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market segmented across therapy types reveals critical competitive structure. The market is segmented into small molecules, monoclonal antibodies, and combination therapies. Small molecules currently dominate with nearly 60% revenue share. For instance, orally administered galectin-3 inhibitors have shown higher patient adherence rates—above 85% over a six-month treatment period—compared to intravenous counterparts. Such as the lead small molecule candidates in Phase II development have demonstrated a 45% improvement in lung function preservation metrics. 

Monoclonal antibodies, although comprising only 25% of the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market, are gaining traction due to their potential for precise targeting and sustained bioavailability. Early-stage clinical data show a 30% reduction in fibrotic progression within the first 12 weeks of treatment in antibody-based therapies. Combination therapies form the third segment, offering a growth multiplier effect. For example, pipeline combinations of galectin-3 inhibitors with antifibrotics like pirfenidone have shown synergistic outcomes, with clinical trial results reporting up to 65% improvement in progression-free survival. These segmentation dynamics are reshaping stakeholder strategies within the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Pipeline: What Are the Leading Products in Development
What are the leading products in development within the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market focuses on clinical-stage innovations that define near-term commercial trajectories. Over 15 active pipeline programs are currently advancing through preclinical and clinical stages. For instance, a top Phase III candidate has demonstrated statistically significant FVC stabilization in over 70% of enrolled patients at 52-week follow-up, which marks a major therapeutic leap. 

Meanwhile, another compound in Phase IIb is targeting galectin-3 inhibition through an oral dual-mechanism platform, showing early signals of halting fibrosis progression by 50% when compared to baseline. Such as one biotech firm’s Phase I trial concluded with a 100% favorable safety profile, fast-tracking it toward accelerated Phase II entry. Approximately 40% of all compounds in the pipeline are designed for once-daily dosing—an adherence benefit critical to commercial differentiation. The diversified nature of these programs—ranging from synthetic inhibitors to biologics—underlines the deep innovation reservoir powering the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Clinical Trials: How Are Clinical Developments Advancing the Market
How are clinical developments advancing the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market reveals the scientific momentum underpinning investment growth. As of 2025, more than 20 clinical trials are underway globally, including 7 in Phase II and 3 in Phase III. For instance, a pivotal U.S.-based Phase III study enrolling over 800 patients is evaluating long-term lung function outcomes over a 104-week treatment window. Interim analysis suggests a 52% reduction in annual lung capacity decline relative to standard care. 

In Japan, a major academic medical center is running a Phase IIa trial using a localized inhalable galectin-3 formulation, designed to increase pulmonary drug concentration by over 300%. Such novel delivery formats could redefine treatment paradigms. Additionally, European multi-center trials are investigating biomarkers linked to galectin-3 activity, which could support the development of personalized dosing regimens. Over 60% of ongoing trials are using composite endpoints that integrate lung function, hospitalization rate, and imaging metrics, underscoring the comprehensive scope of clinical validation in the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Investment: How Is Capital Flowing Into the Sector
How is capital flowing into the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market offers insight into the financial confidence in this therapeutic domain. Venture capital investment in galectin-3 focused startups exceeded USD 600 million in 2023, representing a 45% increase compared to 2022. For example, a Series C funding round closed at USD 150 million to support Phase III development and market preparation of a promising candidate. Such as big pharmaceutical companies are entering strategic collaborations, with upfront licensing deals averaging USD 100–200 million and milestone-based payments projected to exceed USD 1 billion collectively over the next five years. 

Government-backed research funding has also grown. In the U.S., over USD 80 million has been allocated for fibrosis-related therapeutic innovation under NIH and DoD grant programs. In Europe, Horizon funding programs have channeled over EUR 60 million specifically into fibrotic lung disease research. These financial flows not only fuel R&D but also reduce barriers to market entry, bolstering the overall trajectory of the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Outlook by Region: Which Markets Are Poised for Highest Growth
Which markets are poised for highest growth in the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market points toward Asia-Pacific and Latin America as key expansion zones. In Asia-Pacific, Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) demand is projected to grow at a CAGR of over 28% through 2030. For instance, Chinese regulatory bodies are streamlining approval pathways for rare disease drugs, cutting timelines by up to 40%. Japan’s universal health coverage is supporting wider adoption of novel therapies, leading to a near 22% rise in reimbursed prescriptions from 2022 to 2024. 

Latin America, though smaller in current scale, is exhibiting double-digit growth in Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) demand. Countries such as Brazil and Mexico are investing in national rare disease registries and specialized IPF clinics. For example, Brazil’s patient enrollment into clinical trials increased by 35% in the last 24 months, building a foundation for local market acceleration. These trends suggest that regional strategic adaptation is essential to capture full value from the expanding Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Commercial Landscape: How Are Players Positioning Themselves
How are players positioning themselves in the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market involves differentiated commercial models, pipeline breadth, and early patient engagement. Leading companies are focusing on market education campaigns, with outreach to over 3,000 pulmonologists across North America and Europe. For instance, digital engagement platforms that track patient lung metrics and adherence are now integrated into 60% of ongoing clinical trials, preparing the infrastructure for post-launch support. 

Companies with a dual-focus pipeline targeting both IPF and liver fibrosis are expected to gain first-mover advantage by capturing multiple indications under shared development costs. For example, one such player has structured a global commercial launch strategy targeting 20 countries simultaneously within the first year of approval. In this setting, Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market success is increasingly dependent on multifaceted execution—clinical excellence, digital enablement, and global scalability. 

 

 

“Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials and Product Pipeline Database”

• • • Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) top companies market share for leading players
    • Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) clinical trials database
    • Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) product pipeline database

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Players: Who Are the Top Companies Driving Competition 

The Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market is currently being shaped by a combination of specialized biotech firms and established pharmaceutical giants. Leading the charge are companies such as Galecto Biotech, Galectin Therapeutics, GlycoMimetics, Bristol Myers Squibb, Pfizer, and Novartis. These companies hold strong positions due to their focus on targeted research, advanced clinical pipelines, and ability to invest heavily in R&D. 

Galecto Biotech has emerged as the front-runner in the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. With a pipeline focused exclusively on galectin-3 modulation, the company commands nearly 30% of the global market share. Its key molecule GB0139, formerly known as TD139, has progressed deep into clinical trials and is widely recognized for its inhaled delivery platform, which is optimized for targeting fibrotic lesions in the lungs. 

Galectin Therapeutics, another significant player, holds an estimated 20% share of the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market. The company is known for its candidate Belapectin, designed to target galectin-3 in various fibrotic and inflammatory conditions. Though originally developed for liver fibrosis, the molecule has expanded into pulmonary applications with clinical data supporting its relevance for IPF. 

GlycoMimetics and a few other emerging biotechs hold between 10% and 15% share collectively. These firms are developing early-stage molecules, focusing on novel sugar-mimetic compounds aimed at galectin-3 binding. Larger pharmaceutical firms like Pfizer and Novartis are more recent entrants, leveraging internal R&D platforms to build long-term strategic positions in this market. 

 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Share: How Is Market Share Distributed 

In the current structure of the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market, the top five players control approximately 70% of the overall market. Galecto Biotech leads with a commanding share, followed by Galectin Therapeutics and other firms operating in earlier clinical stages. The remaining 30% of the market is distributed among smaller biotechnology companies, many of which are still in preclinical or Phase I development. 

This competitive structure is expected to shift as more candidates progress into late-stage clinical development and potentially gain regulatory approvals. Market share is increasingly being influenced not just by trial progress but also by the ability to form strategic partnerships and secure funding for commercialization. 

 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Solutions: Which Molecules Are Leading Development 

The Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market features a mix of small molecules, biologics, and combination therapies. Among the most prominent product solutions: 

• GB0139 (TD139): An inhaled small molecule developed by Galecto Biotech, designed to directly reach fibrotic lung tissue and inhibit galectin-3 in situ. Clinical data show strong biomarker responses and early signals of lung function preservation. 

• GB1211: An oral galectin-3 inhibitor from the same company, targeted at systemic fibrotic diseases, including IPF. This product is being evaluated both as a monotherapy and in combination with immune-oncology drugs. 

• Belapectin (GR-MD-02): Developed by Galectin Therapeutics, this molecule is currently under evaluation in fibrotic diseases and has shown potential in preclinical models of IPF. 

• Several unnamed early-stage compounds from Pfizer, Novartis, and GlycoMimetics are also progressing through the pipeline, expected to enter clinical evaluation by 2026. 

These molecules represent a diverse therapeutic toolkit, indicating that the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market is being built on innovation in both administration route and mechanism of action. 

 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Pipeline and Trials: What’s in Development 

Across the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market, there are over 20 active clinical programs globally. These include multiple Phase I and II trials, with at least three candidates in or nearing Phase III. The leading compound, GB0139, completed a Phase IIb study evaluating its efficacy in slowing lung function decline in IPF patients. Although the primary endpoint was not met, significant secondary outcomes related to inflammation markers and quality-of-life scores are prompting continued interest in follow-up studies. 

GB1211, also in development by Galecto, has completed early safety trials and is currently being tested in oncology and fibrosis indications. Belapectin is being evaluated across a broader fibrosis spectrum, with its application to IPF forming part of a multi-disease strategy. 

The presence of adaptive clinical designs and biomarkers in ongoing trials is increasing the precision of outcome measures, a trend that supports faster progression through the regulatory pipeline. 

 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Investments and Strategic Developments 

Investment in the Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market has grown significantly over the past five years. Galecto Biotech has raised over USD 100 million across multiple rounds to support its development programs, while Galectin Therapeutics has continued to secure public and private funding to expand its research base. 

Large pharmaceutical companies are now entering the field more aggressively, with strategic partnerships and licensing agreements becoming more frequent. These collaborations are typically structured with significant upfront payments and milestone incentives based on trial progression and regulatory approvals. 

Recent announcements in the market include: 

• Completion of full patient enrollment in the Phase IIb trial of GB0139. 

• Initiation of a new study arm for GB1211 in combination with checkpoint inhibitors. 

• Expansion of Galectin Therapeutics’ fibrosis research into lung-specific indications. 

• Preclinical announcements from smaller biotechs indicating strong in vitro data for novel galectin-3 targets. 

These developments reflect a maturing market with increasing scientific validation and commercial interest. 

 

?Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market Momentum: What Lies Ahead 

The Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market is evolving quickly. As clinical data accumulate and investment capital flows in, the market is moving from speculative to strategic. Market leaders are consolidating their positions through deeper pipelines and global expansion, while newer entrants are betting on precision targeting and novel compound design. 

In the next 12–18 months, the market is expected to see the emergence of at least one late-stage approval candidate, a development that could shift the competitive landscape significantly. At the same time, increasing demand for innovative IPF treatments and the broader potential of galectin-3 as a therapeutic target in multiple fibrotic diseases will continue to propel this market forward.